UnknownPhase 3NCT05156528

Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years

Studying Shigellosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Principal Investigator: Lin Du
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Intervention: S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine(biological)
Enrollment: 21000 enrolled
Eligibility: 5 years · All sexes
Timeline: 2021 – 2024

Study locations (9)

Hezhou Center for Disease Control and Prevention, Hezhou, Guangxi, China
Luzhai Center for Disease Control and Prevention, Luzhai, Guangxi, China
Sanjiang Center for Disease Control and Prevention, Sanjiang, Guangxi, China
Zhongshan Center for Disease Control and Prevention, Zhongshan, Guangxi, China
Yongnian Center for Disease Control and Prevention, Handan, Hebei, China
Yuanshi Center for Disease Control and Prevention, Huaiyang, Hebei, China
Panzhihua Center for Disease Control and Prevention, Panzhihua, Sichuan, China
Zigong Center for Disease Control and Prevention, Zigong, Sichuan, China
Fushun Center for Disease Control and Prevention, Zigong, Sichuan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05156528 on ClinicalTrials.gov

Other trials for Shigellosis

Additional recruiting or active studies for the same condition.

See all trials for Shigellosis →

← Back to all trials